uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience
Show others and affiliations
1994 (English)In: Supportive Care in Cancer, ISSN 0941-4355, E-ISSN 1433-7339, Vol. 2, no 6, 393-399 p.Article in journal (Refereed) Published
Abstract [en]

An open, noncomparative, Nordic multicenter study was carried out during 1991-1992 to evaluate the 5-HT3 receptor antagonist tropisetron (Navoban) as an antiemetic agent for various types of cancer chemotherapy. A total of 630 patients were recruited from 15 centers in Sweden, Denmark, and Finland. Gynecological cancers (60%), breast cancer (15%), and lung cancer (10%) were the main diagnoses. Prior experience of chemotherapy was documented in 338 patients (54%). In 260 patients (41%), cisplatin was part of the cytostatic regimen. Carboplatin (23%), doxorubicin (27%), and epidoxorubicin (24%) were also frequently included. In all, 23 cytostatic agents were used in various combinations. The mean number of courses studied was 4.6 (range 1-19). Altogether, 394 of 619 evaluable patients (64%) were completely protected from acute nausea and vomiting during the first course of chemotherapy. Delayed nausea and vomiting were completely prevented in 45%-73% (days 2-6) in the complete series. Treatment efficacy remained stable (60%-79%) during ten consecutive courses of chemotherapy. With noncisplatin regimens, complete protection from acute nausea and vomiting was achieved in 72% compared with 52% for cisplatin regimens (P < 0.0001). Patients without prior experience of chemotherapy had higher control rates of acute nausea and vomiting (72%) compared to patients treated before (57%) during the first course, but not later on. There were no differences in delayed nausea and vomiting.

Place, publisher, year, edition, pages
1994. Vol. 2, no 6, 393-399 p.
Keyword [en]
Adult, Aged, Aged; 80 and over, Antiemetics/adverse effects/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols/*adverse effects, Female, Finland, Humans, Indoles/adverse effects/*therapeutic use, Male, Middle Aged, Nausea/chemically induced/*prevention & control, Neoplasms/drug therapy, Scandinavia, Sex Factors, Treatment Outcome, Vomiting/chemically induced/*prevention & control
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-21443DOI: 10.1007/BF00344055PubMedID: 7858934OAI: oai:DiVA.org:uu-21443DiVA: diva2:49216
Available from: 2006-12-28 Created: 2006-12-28 Last updated: 2010-10-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=7858934&dopt=Citation

Search in DiVA

By author/editor
Tiensuu Janson, Eva
By organisation
Department of Medical Sciences
In the same journal
Supportive Care in Cancer
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 186 hits
ReferencesLink to record
Permanent link

Direct link